Novigenix utilizes an AI-driven RNA sequencing platform to profile immune responses, enabling precise risk assessment and treatment predictions for cancer patients. The company addresses the challenge of heterogeneity in cancer treatment by providing actionable data for drug target discovery and early detection, particularly in colorectal cancer.
Funding
$1.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cancer treatment is often hindered by the heterogeneity of the disease and the variability in patient responses, making it difficult to predict treatment outcomes and develop effective therapies. Current methods lack precise information to guide therapy development and clinical decision-making, leading to uncertainty in treatment strategies.
Solution
Novigenix offers an AI-driven RNA sequencing platform that profiles immune responses to provide precise and predictive insights for cancer patients. By analyzing blood RNA and systemic immune response signatures, the platform delivers data on cancer risk, stage, and likely response to immunotherapy. This enables more informed clinical decisions, facilitates drug target discovery, and accelerates the development of effective therapeutics. The platform captures the cancer immunity cycle during disease progression and response to therapy, providing a comprehensive understanding of the interplay between the immune system and cancer.
Target Audience
The primary customers are biopharma companies involved in drug development and drug target discovery, as well as clinicians seeking precise information to guide cancer treatment decisions.
Features
- AI-driven analysis of blood RNA to profile immune response signatures
- Predictive biomarker discovery and validation using large patient datasets
- Identification of drug targets based on immune profiling data
- Monitoring of the cancer immunity cycle during disease progression
- Prediction of patient response to immunotherapy